Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. Show more
4660 La Jolla Village Drive, San Diego, CA, 92122, United States
Start AI Chat
Market Cap
3.646M
52 Wk Range
$1.29 - $52.06
Previous Close
$1.39
Open
$1.39
Volume
58,450
Day Range
$1.33 - $1.39
Enterprise Value
-1.595M
Cash
12.71M
Avg Qtr Burn
-1.589M
Insider Ownership
1.69%
Institutional Own.
11.73%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Gemini (IV) Details Stage 3-4 Chronic Kidney Disease | Phase 1 Update |